KalVista Publishes Phase 3 Data Demonstrating its Potential Treatment in Hereditary Angioedema

  Late-breaking data from phase 3 KONFIDENT trial of sebetralstat published in NEJM and presented concurrently at the European Academy of Allergy and Clinical Immunology Congress 2024 –

– Interim data from KONFIDENT-S open-label trial show median time to treatment of 9 minutes and median time to beginning of symptom relief for laryngeal attacks 1.3 hours –

https://www.businesswire.com/news/home/20240531104408/en